Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 6/20 | 0.75 |
| ▸ | SLC6A13 | Q9NSD5 | 6/20 | 0.75 |
| ▸ | SLC6A12 | P48065 | 5/20 | 0.75 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.75 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.75 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.75 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.75 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.75 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.75 |
| ▸ | CPN1 | P15169 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2918774 | 1.00 | SLC6A11 (0.75) | SLC6A11SLC6A13SLC6A12SLC6A1GABRA5 | |
| SCHEMBL2569289 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL177340 | 0.87 | — | — | |
| SCHEMBL2450833 | 0.86 | — | — | |
| SCHEMBL374930 | 0.86 | — | — | |
| SCHEMBL24478321 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL22655757 | 0.84 | SLC6A1 (0.96) | SLC6A11SLC6A13SLC6A12SLC6A1GABRA5 | |
| Hydrochloric Acid SCHEMBL21774701 | 0.84 | SLC6A1 (0.96) | SLC6A11SLC6A13SLC6A12SLC6A1GABRA5 | |
| Hydrochloric Acid SCHEMBL21774704 | 0.84 | SLC6A1 (0.96) | SLC6A11SLC6A13SLC6A12SLC6A1GABRA5 | |
| SCHEMBL1225755 | 0.82 | SLC6A1 (0.77) | SLC6A11SLC6A13SLC6A12SLC6A1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11607466-B2 | Tumor and immune cell imaging based on PD-L1 expression | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-03-21 | — | — | US | claimed |
| CN-118698506-A | Preparation method of porous gallic acid modified chitosan-based composite aerogel material | 渤海大学 | 2024-09-27 | — | — | CN | disclosed |
| WO-2023245100-A1 | ANTIMICROBIAL NCR13 VARIANT PEPTIDES | Vestaron Corporation (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11607466-B2 | Tumor and immune cell imaging based on PD-L1 expression | CD274, PDCD1LG2, PDCD1 | SLC6A11 4463/4885SLC6A13 4401/4885SLC6A12 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.